Stanley Morrow, DO
Family Medicine · Hackleburg, ALNPI 1386656619
Payments from drug & device makers
Across 245 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$349
- Pfizer$338
- Novo Nordisk$300
- AbbVie$259
- AstraZeneca$243
- Sunovion Pharmaceuticals Inc.$236
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,395100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $349 |
| Pfizer | 34 | $338 |
| Novo Nordisk | 17 | $300 |
| AbbVie | 30 | $259 |
| AstraZeneca | 8 | $243 |
| Sunovion Pharmaceuticals Inc. | 15 | $236 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $235 |
| Novartis | 13 | $180 |
| Amgen(2 entities) | 13 | $178 |
| Johnson & Johnson | 12 | $150 |
| Lilly USA, LLC | 8 | $123 |
| Merck | 4 | $70 |
| Ironwood Pharmaceuticals, Inc | 4 | $69 |
| Corcept Therapeutics | 4 | $59 |
| Collegium Pharmaceutical, Inc. | 4 | $58 |
| Amarin Pharma, Inc. | 3 | $58 |
| Indivior Inc. | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $53 |
| Boehringer Ingelheim | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Eisai Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Genentech USA, Inc. | 3 | $37 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Exact Sciences | 1 | $24 |
| Antares Pharma, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
How this compares
$3,395 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 128 | $140,969 |
| EliquisApixaban | 262 | $119,230 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 3,425 | $93,114 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $85,505 |
| FarxigaDapagliflozin Propanediol | 90 | $60,493 |
| XareltoRivaroxaban | 77 | $53,254 |
| MyrbetriqMirabegron | 86 | $48,175 |
| OzempicSemaglutide | 38 | $41,442 |
| JanuviaSitagliptin Phosphate | 56 | $40,196 |
| VraylarCariprazine Hcl | 30 | $39,946 |
| LinzessLinaclotide | 62 | $39,298 |
| JardianceEmpagliflozin | 45 | $35,263 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 172 | $34,074 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,191 | $29,024 |
| GemtesaVibegron | 84 | $28,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $123 | $165,170152 claims |
| PfizerEliquis, Lyrica | $338 | $128,595273 claims |
| GSKTrelegy Ellipta | $349 | $85,505115 claims |
| AbbVieVraylar, Linzess | $259 | $79,24592 claims |
| AstraZenecaFarxiga, Symbicort | $243 | $71,372131 claims |
| Johnson & JohnsonXarelto, Invokana | $150 | $68,75296 claims |
| MerckJanuvia, Janumet | $70 | $56,40075 claims |
| Novo NordiskOzempic, Rybelsus | $300 | $54,66552 claims |
| Boehringer IngelheimJardiance | $50 | $35,26345 claims |
| NovartisEntresto | $180 | $19,53218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $53 | $11,58615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Hackleburg
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.